PresentationThe clock strikes 3:00 p.m., and we welcome viewers here to Vivesto's business update. Today, we will hear about the company with a focus towards the company's project portfolio, specifically Paccal Vet and Cantrixil in the midst of a capital raise. We will hear from internal speakers of the company as well as external speakers from both clinic and academia. And we will, of course, finish with a Q&A. [Operator Instructions]. But first and foremost, and without further ado, we now turn to Chairma ...

Summary of Vivesto's Business Update Conference Call Company Overview - **Company**: Vivesto - **Focus**: Oncology-driven biotech company specializing in innovative treatments for both human and veterinary medicine, particularly in cancer treatment [2][3] Key Programs Paccal Vet - **Description**: A proprietary formulation of paclitaxel designed for veterinary use, specifically targeting hemangiosarcoma in dogs and solid tumors in cats [7][22] - **Current Studies**: - **Dog Study**: Ongoing pilot study for dogs with splenic hemangiosarcoma, with 13 out of 18 dogs recruited. Expected top-line data in Q2 2026. Interim results show a median overall survival of 138 days compared to 60-86 days for standard care [24][25] - **Cat Study**: Dose-finding study for cats with various solid tumors, with 8 out of 12 cats recruited. Preliminary results indicate good tolerability and some clinical responses [26][28] Cantrixil - **Description**: A new proprietary chemotherapy agent targeting hematological cancers, currently in late-stage preclinical development [8][60] - **Focus**: Acute myeloid leukemia (AML), with plans to enter clinical development after 2026. Cantrixil has shown synergistic effects when combined with standard care agents [62][63] Market Dynamics - **Veterinary Oncology Growth**: The global companion animal health market is estimated to grow to $40 billion annually, driven by increased pet ownership and willingness to invest in advanced therapies [15][10] - **Unmet Medical Needs**: There is a significant demand for effective cancer treatments in veterinary medicine, with a high lifetime risk of cancer in pets, particularly in older dogs [16][17] Financial Strategy - **Capital Raise**: Vivesto is planning a rights issue fully supported by existing shareholders, expected to provide funding until mid-2027. Proceeds will support ongoing studies and regulatory activities [11][12] - **Partnership Opportunities**: The company aims to initiate partnering activities for both Paccal Vet and Cantrixil to enhance development speed and commercialization [12] Regulatory Support - **Designations**: Paccal Vet has received MUMS designation from the FDA, providing incentives for development in veterinary oncology. The EMA has also granted limited market classification [49][50] Conclusion - Vivesto is positioned at a critical juncture with a focused oncology strategy, strong backing from shareholders, and promising clinical data for its key programs. The company aims to address significant unmet medical needs in both human and veterinary oncology, with a clear path towards market approval and potential partnerships to enhance its capabilities [3][11][60]

Core Viewpoint - Kazia Therapeutics Limited has sold all intellectual property and trademark rights to its oncology drug candidate Cantrixil to Vivesto for USD $1 million, providing non-dilutive funding to advance its clinical-stage pipeline [1][3]. Group 1: Transaction Details - Kazia will receive USD $1 million from Vivesto for the rights to Cantrixil [1]. - Vivesto had previously licensed exclusive global development and commercialization rights for Cantrixil from Kazia in March 2021 [2]. - Vivesto has decided not to pursue Cantrixil for ovarian cancer and is now exploring it for hematological cancers [2]. Group 2: Company Overview - Kazia Therapeutics is an oncology-focused drug development company based in Sydney, Australia, with a lead program, paxalisib, targeting multiple forms of brain cancer [4]. - Paxalisib has undergone ten clinical trials and has received various designations from the FDA, including Orphan Drug Designation and Fast Track Designation for glioblastoma [4]. - The company is also developing EVT801, a small molecule inhibitor of VEGFR3, which has shown activity against a broad range of tumor types [4].